Rhythm Pharmaceuticals Inc (1RV F) stock market data APIs
€83.1528
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
Rhythm Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Prev. Close
83.1528
Open
83.1528
High
83.1528
Low
83.1528
52 wk Range
41-89
Market Cap
5 513 M
Shares Outstanding
66 420 K
Revenue
156 M
EPS
-0.75
Beta
2.238
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rhythm Pharmaceuticals Inc data using free add-ons & libraries
Get Rhythm Pharmaceuticals Inc Fundamental Data
Rhythm Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 156 M
- EBITDA: -175 910 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rhythm Pharmaceuticals Inc News
New
Citizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the 10 Hot Mid Cap Stocks to Buy Now. On August 21, Citizens JMP reaffirmed a Market Outperform rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM...
FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 20, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced that the FDA had...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Rhythm Pharmaceuticals, Inc. BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the liv...
FDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM)
On August 20, 2025, Rhythm Pharmaceuticals announced that the FDA accepted its supplemental New Drug Application for setmelanotide in acquired hypothalamic obesity, granting the submission Priority Re...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
